Remove Blog Remove Clinical Research Remove Research
article thumbnail

Managing Opportunities and Risks in Generative AI Use for Clinical Research

PPD

Generative artificial intelligence (AI) has captured global attention for its transformative potential across industries, and nowhere is the promise greater — or more fraught — than in health care and clinical research. Accelerate your clinical research with our drug development digital solutions from Thermo Fisher Scientific.

article thumbnail

The Growing Trend of Patient-Led Clinical Research in Rare Disease

Conversations in Drug Development Trends

By: Juliane Mills, Senior Director, Therapeutic Strategy Lead, Rare Disease The rise of patient-led clinical research, particularly in rare disease, represents a significant shift in the clinical trial landscape. Why Is There an Increase in Patient-Led Rare Disease Research?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Challenges and Future Trends in Biomarker Analysis for Clinical Research: What’s Ahead in 2025

Crown Bioscience

These innovations promise to enhance the precision and efficacy of early-stage research, setting a solid foundation for subsequent clinical applications and enabling the development of more personalized medicine. In this blog post, we’ll focus on the preclinical innovations and trends expected to reshape biomarker analysis.

article thumbnail

Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development

FDA Law Blog: Drug Discovery

Background on the Grants Program Launched as part of the Orphan Drug Act of 1983, this program aims to encourage research and development of drugs, biologics, medical devices, and medical foods for rare diseases, defined as conditions that affect fewer than 200,000 people in the U.S. The seven awardees included six early-stage trials (e.g.,

article thumbnail

Winning Regulatory Trust: Six Smart Strategies for Emerging Biotechs

PPD

This blog reviews six of the most valuable aspects of regulatory communication and relationship building that, when executed properly, are often able to enhance a therapy’s chance of getting to market. Before these meetings, it is important to do the necessary research on the agency involved and what information they will want.

article thumbnail

How FSP Models Help Biotech Companies Augment Their Clinical Development Needs

PPD

This blog explores the value of functional service provider (FSP) models and how they help biotech companies augment their clinical development needs. FSP outsourcing is growing faster than FSO.

article thumbnail

Advancing and Safeguarding Clinical Research for a Better Tomorrow

Advarra

Institutional review boards (IRBs) play a crucial role in the ever-evolving field of clinical research. Innovations in fields such as immunotherapy, cancer and chronic diseases owe their existence to clinical trials, which judiciously test and evaluate safety and efficacy.